Saccharomyces boulardii
Best-in-class: Sacro-B
A beneficial probiotic YEAST (not a bacterium) that is uniquely resistant to antibiotics — making it ideal support during and after antibiotic courses.
Saccharomyces boulardii quick facts
| Suggested dose | One serving daily, especially during/after antibiotics or travel. |
| How often | Daily, especially during antibiotics |
| Who it's for | Anyone on antibiotics, traveling, or with acute gut disruption. |
Strong meta-analysis support for antibiotic-associated diarrhea and for Clostridioides difficile, which is more robust evidence than most probiotics have. The antibiotic-compatibility is genuinely useful and under-exploited. The real caution: it should not be used in anyone significantly immunocompromised or with a central line, where fungemia has been documented.
How Saccharomyces boulardii actually works
A yeast rather than a bacterium, which is the defining property: antibacterial antibiotics do not kill it, so it can run concurrently with a course rather than after it. It works by competitively excluding pathogens, degrading bacterial toxins directly, and stimulating secretory IgA.
Where to get Saccharomyces boulardii
Buy Sacro-B at Thorne →What it is, why it recurs, and where this fits — free to read.
The H. pylori Protocol →What it is, why it recurs, and where this fits — free to read.
The evidence for Saccharomyces boulardii
Graded by what exists behind each claim.
✅ Clinically validated
- Strong RCT/meta-analysis support for preventing antibiotic-associated and traveler's diarrhea.
- Because it's a yeast, antibiotics don't kill it — it works alongside them.
📊 Correlative data
- Antibiotic use and travel track with gut disruption that S. boulardii mitigates.
🧪 Theoretical / extrapolated benefits
- Anti-inflammatory and pathogen-crowding mechanisms are well-characterized for this strain.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Saccharomyces boulardii actually does
The most consequential fact about this product is taxonomic: it is a yeast, not a bacterium, and almost every useful property follows from that. Antibacterial antibiotics have no target in a eukaryote, so this organism survives a course of amoxicillin or clindamycin that would sterilize a Lactobacillus preparation. That is why it is the probiotic with the most coherent rationale for use during antibiotic therapy, and it is a structural argument rather than a marketing one.
The second taxonomic fact is that it is not a separate species at all. Molecular work places boulardii as a variety of Saccharomyces cerevisiae rather than as a distinct species, and the authentication method built for it is titled accordingly — high-resolution melting analysis for Saccharomyces cerevisiae var. boulardii Borkowska 2024. What separates it from baker's yeast is a set of phenotypic differences, principally an optimal growth temperature near 37 degrees Celsius and acid tolerance, not a different genome.
Its mechanisms are enzymatic and physical rather than colonizing. It secretes a 54-kilodalton serine protease that cleaves Clostridioides difficile toxin A and its intestinal receptor; it secretes a phosphatase that dephosphorylates bacterial lipopolysaccharide, blunting endotoxin signaling; its cell wall provides mannose residues that pathogenic Escherichia coli type 1 fimbriae bind to instead of binding the enterocyte. The narrative review of the deposited strain's properties is where these are assembled Gopalan 2023.
It does not colonize, and that is a feature. Because it cannot establish permanently, its concentration in the gut is a function of dosing rate, and it clears within days of stopping. A probiotic that washes out is one whose effects should disappear predictably, which is a testable property and one that distinguishes it from bacterial preparations claiming durable engraftment Abid 2022.
It also does trophic and metabolic things to the epithelium. Secreted polyamines support enterocyte maturation and brush-border disaccharidase activity, which is a plausible route to the effect on osmotic diarrhea. And it raises secretory immunoglobulin A in the lumen, which is a mucosal rather than a systemic immune effect.
Cell, rodent, human — and where it stops
The human evidence here is unusually good for a probiotic, and the translation problem is not biology. It is which strain is in the capsule.
In people, for antibiotic-associated diarrhea. An overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children is the highest tier of evidence synthesis this field offers Yang 2023. An overview of reviews sits above a meta-analysis and it exists because there were enough reviews to warrant one.
In people, for Helicobacter pylori eradication. A meta-analysis of Saccharomyces boulardii as adjuvant therapy for eradication reports on both efficacy and safety Li 2025. That is a well-defined clinical setting with a hard endpoint, which makes it more interpretable than most probiotic trials.
And in a formal review of the organism as a probiotic yeast. The properties of the deposited CNCM I-745 strain have been reviewed as a body Gopalan 2023, alongside broader reviews of probiotic Saccharomyces Abid 2022.
Here is the obstacle, and it is severe enough to have generated its own analytical method. Probiotic effects are strain-specific. The trials belong to a deposited strain. High-resolution melting analysis had to be developed to authenticate Saccharomyces cerevisiae var. boulardii in probiotic-enriched food matrices Borkowska 2024, and methods like that get built when the labels cannot be trusted to identify what is inside.
The second obstacle is viability. Colony-forming units are a count of living cells at the time of testing. A yeast preparation loses viability with heat and humidity, so a label figure guaranteed at manufacture and a label figure guaranteed at expiry are different promises, and only one of them describes what the reader swallows.
Saccharomyces boulardii — which form, and does it matter
The strain designation is the product, and it is either printed or it is missing. The clinical literature belongs to a deposited strain with a collection number — CNCM I-745 is the designation that appears in the review of its properties Gopalan 2023. A capsule labeled only “Saccharomyces boulardii” names a variety of a common yeast species and identifies nothing that the trials studied.
That is not a pedantic point, because authentication turned out to be necessary. Somebody built a molecular method to confirm whether a product contains this variety at all Borkowska 2024. Analytical methods are developed to solve problems that exist.
Lyophilized and non-lyophilized preparations behave differently. Freeze-dried yeast has to rehydrate and resume metabolic activity before it does anything, and the reconstitution kinetics differ between preparations. The general reviews of probiotic yeast treat preparation as a variable rather than a detail Abid 2022, and a reader comparing two products on colony-forming units alone has ignored it.
Colony-forming units are the wrong number to compare across products for a second reason. A yeast cell is far larger than a bacterial cell, so a yeast product at a few billion units and a bacterial product at fifty billion are not on the same scale by mass or by surface area. Comparing a boulardii dose with a Lactobacillus dose by the number on the front is comparing counts of different objects.
And the excipients are part of the form. Yeast preparations are commonly carried in lactose. For somebody taking a probiotic because of diarrhea, a lactose carrier is not a trivial ingredient, and it is on the label rather than in the literature.
What would have to be true, and how you would know it was not
1. Predict the effect is prophylactic and time-locked to the antibiotic course. Starting on day one of antibiotics and continuing for a week afterward is the design the reviews describe Yang 2023. Prediction: starting after diarrhea has already begun produces a smaller effect, because the mechanisms are competitive and toxin-degrading rather than restorative.
2. Predict it washes out, and use that as the test. Because it does not colonize Abid 2022, stopping should return stool frequency and consistency to baseline within about a week. Somebody whose symptoms stay improved a month after stopping was probably going to improve anyway, and that is a genuinely useful self-test.
3. Predict a measurable difference in eradication rate rather than in symptoms. In Helicobacter pylori therapy the endpoint is a urea breath test or stool antigen test at least four weeks after finishing treatment Li 2025. Prediction: the adjuvant effect appears as fewer treatment-limiting side effects and better completion, with eradication following from that.
4. Predict no change in any systemic inflammatory marker. The mechanisms are luminal — protease, phosphatase, adhesion decoy Gopalan 2023. Baseline and eight-week hs-CRP should be unchanged. A fall would suggest something systemic is happening that the current mechanism does not explain.
5. The prediction that would embarrass the shelf. Buy six products labeled Saccharomyces boulardii and authenticate them Borkowska 2024, then plate them for viable count. Prediction: strain identity and viable count both vary, and neither correlates with price. This is a weekend of laboratory work and nobody has published it.
What nobody has tested yet
Nobody has published the market authentication survey. The method exists Borkowska 2024. Applying it to on-market capsules, with viable counts beside it, would tell a reader whether the strain-specific literature applies to what they can buy. Its absence is why every recommendation on this page has to be hedged with the strain designation.
Nobody has run a dose-response study. Products range across an order of magnitude in colony-forming units and the trials used particular doses. Whether more is better, or whether the effect plateaus, has not been established for this organism, which means every dosing recommendation is copied rather than derived.
Nobody has quantified the fungemia risk properly. Bloodstream infection with this yeast is documented in patients with central venous catheters and critical illness Rannikko 2021. What is missing is a denominator: case counts exist and exposure counts do not, so the risk per patient treated in a given setting cannot be stated.
And nobody has tested it against the newer comparator. For recurrent Clostridioides difficile infection, the field has moved toward microbiota-based therapies. Whether this yeast adds anything alongside them, or is superseded by them, has not been studied Yang 2023.
Saccharomyces boulardii — its own safety story, not its category's
This product has a documented serious adverse event and it is specific to the fact that it is a live organism. Fungemia and other fungal infections have been reported in association with the use of Saccharomyces boulardii probiotic supplements Rannikko 2021. That is the defining safety fact here, it is not shared with most of this shelf, and it is the reason the population question below is not boilerplate.
The route matters as much as the patient. Reported cases cluster around central venous catheters, and one recognized route is environmental: the capsule is opened at the bedside, yeast becomes airborne, and hands or the catheter hub are contaminated. That means the risk is not only to the person swallowing it but to the patient in the next bed with a line in.
Who should not take it, stated plainly. Anybody with a central venous catheter, anybody critically ill, anybody immunocompromised including after transplant or during chemotherapy, and anybody with a prosthetic heart valve. In those groups a live yeast is a different proposition from a nutritional supplement Rannikko 2021.
The interaction that is often missed is with antifungals. Fluconazole and its relatives will kill this organism, because it is a yeast. Taking both at once is not dangerous; it is simply futile, and somebody paying for a probiotic while on an antifungal should know that. The corresponding point is the useful one: antibacterial antibiotics do not touch it Gopalan 2023.
In healthy people, the ordinary side effects are unremarkable. Gas, bloating and constipation are the common reports, and the reviews of probiotic Saccharomyces treat it as well tolerated in immunocompetent populations Abid 2022. The gap between that sentence and the paragraph above it is the entire risk story: this is a safe supplement for most people and a live organism for everybody.
Sources read for this page
- Gopalan S. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. Cureus 2023 · PMID 37927652
- Li M. Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis. Front Cell Infect Microbiol 2025 · PMID 40012609
- Yang Q. Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children. Front Pharmacol 2023 · PMID 37564180
- Borkowska M. High-Resolution Melting Analysis Potential for Saccharomyces cerevisiae var. boulardii Authentication in Probiotic-Enriched Food Matrices. BioTech (Basel) 2024 · PMID 39584905
- Rannikko J. Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements. Emerg Infect Dis 2021 · PMID 34287140
- Abid R. Probiotic Yeast Saccharomyces: Back to Nature to Improve Human Health. J Fungi (Basel) 2022 · PMID 35628700
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: Whether the diarrhea that normally follows your antibiotic courses shows up this time. This is prevention, so the read-out is an event that does not happen, and a non-event only carries information if you know your own rate from previous courses.
- How long before it means anything: The course itself plus the two weeks after it. Antibiotic-associated diarrhea appears during treatment or shortly afterward, so the antibiotic sets the window, not the yeast.
- What will fool you: The drug you were given. Diarrhea rates differ enormously between antibiotic classes, so a quiet course on one prescription says nothing about the yeast if last time was a different one. Being a yeast is also why this survives the antibiotic, so a previous failure with a bacterial probiotic is not evidence about this one.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Saccharomyces boulardii — safety & side effects
- Gas, bloating and constipation.
- It is a yeast, and fungemia has been reported in critically ill patients and those with central lines — the same contraindication as bacterial probiotics, with the added point that it is not killed by antibacterial antibiotics.
- Do not take with antifungal medication — it will simply be killed. Avoid with yeast allergy.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Saccharomyces boulardii in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Saccharomyces boulardii
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | Anemia is the commonest sign of a gut absorbing badly |
| Ferritin | Iron is the first thing malabsorption takes |
| Vitamin B12 | The second thing, and the one with permanent consequences |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Separates inflammatory bowel disease from IBS |
The Gut Health & Absorption panel covers these in one order — 11 markers, $208.80 with the discount applied.
Check results you already have → · All 103 markers A–Z
Saccharomyces boulardii — frequently asked questions
What is Saccharomyces boulardii?
A beneficial probiotic YEAST (not a bacterium) that is uniquely resistant to antibiotics — making it ideal support during and after antibiotic courses.
What is the suggested dose of Saccharomyces boulardii?
One serving daily, especially during/after antibiotics or travel. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Saccharomyces boulardii dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Saccharomyces boulardii?
Coach Cam sources Saccharomyces boulardii from Thorne, with 10% off auto-applied at checkout — use the buy link on this page.
Saccharomyces boulardii inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Saccharomyces boulardii is used for
Saccharomyces boulardii appears under 2 goals in the goal router.
Related Gut & Digestion supplements
Where this goes next
Saccharomyces boulardii is the microbiome arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.